Document Detail


Interleukin-2 inhalation therapy in renal cell cancer: a case report and review of the literature.
MedLine Citation:
PMID:  18712176     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Renal cell carcinoma (RCC) is the most common malignancy of the kidney. One third of RCC presents metastatic disease at the time of diagnosis, usually leading to a fatal outcome. Small response rates were seen with most cytotoxic agents including gemcitabine and vinorelbine, whereas systemic therapy with high doses of interleukin 2 (IL-2) has been shown to provide durable complete remissions. However, in consideration of its severe toxicity, IL-2 immunotherapy is restricted to selected patients. Aerosol IL-2 has been introduced as an alternative therapy in cancer patients. However, only very few data are available on its use in patients with pulmonary metastatic RCC. This paper briefly summarizes current clinical experience with the use of inhaled IL-2 therapy, either as a single therapy or in combination with other treatments. In addition, we report on a male patient with pulmonary metastasized RCC who achieved a durable complete response to combined gemcitabine/vinorelbine and interleukin-2 inhalation therapy.
Authors:
Girolamo Del Monte; Patrizia Ferroni; Sabrina Mariotti; Emanuela Fossile; Fiorella Guadagni; Mario Roselli
Related Documents :
9131506 - Renal disease. ii. the clinical impact of recombinant human erythropoietin.
3755306 - Elimination of atracurium in humans: contribution of hofmann elimination and ester hydr...
11905416 - Clinical pathways for managing patients receiving interleukin 2.
18559586 - Tissue-based research in kidney cancer: current challenges and future directions.
10928156 - Thymidine phosphorylase expression in gastric cancer in association with proliferative ...
7829216 - Clinical validation of the new elsa-ca 125 ii assay: report of a european multicentre e...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  In vivo (Athens, Greece)     Volume:  22     ISSN:  0258-851X     ISO Abbreviation:  In Vivo     Publication Date:    2008 Jul-Aug
Date Detail:
Created Date:  2008-08-20     Completed Date:  2008-09-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8806809     Medline TA:  In Vivo     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  481-8     Citation Subset:  IM    
Affiliation:
Medical Oncology, Department of Internal Medicine, University of Rome Tor Vergata, Tor Vergata Clinical Center, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Renal Cell / metabolism*
Deoxycytidine / administration & dosage,  analogs & derivatives
Gene Expression Regulation, Neoplastic*
Humans
Immunotherapy / methods
Interleukin-2 / administration & dosage*
Kidney Neoplasms / metabolism*
Male
Neoplasm Metastasis
Tomography, X-Ray Computed
Treatment Outcome
Vinblastine / administration & dosage,  analogs & derivatives
Chemical
Reg. No./Substance:
0/Interleukin-2; 103882-84-4/gemcitabine; 71486-22-1/vinorelbine; 865-21-4/Vinblastine; 951-77-9/Deoxycytidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  APE1 and XRCC3 polymorphisms and myocardial infarction.
Next Document:  A color Doppler ultrasound-based comparative study between stavudine and non-stavudine regimens in t...